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Center (WTC) attack of September 11, 2001 (9/11), both in
patients living near or geographically distant from New York City
(1,2). By contrast, another work found that, compared with control
years, there was no disproportionate increase in cardiovascular
mortality after the terrorist attacks in New York City (3). A major
advantage of this latter study is to compare the variation in the
occurrence of events in 2001 and in the years since 1997 (an
analysis of “the variation of the variations”).
We believe interpretation of the results of Steinberg et al. (1)
and of Shedd et al. (2) might therefore be doubtful. Similarly, if
the investigators had also found that arrhythmic events were more
frequent on 9/11 between 9 AM and 12 noon (after the attack) than
between 5 AM and 8 AM (before the attack), it would be difficult to
make a direct relation between this phenomenon and the attack,
because there is a well-known diurnal variation of cardiac events,
with more frequent events in the morning hours (4).
Because a circannual variation of malignant ventricular tachy-
arrhythmias in patients with implantable cardioverter-defibrillators
has clearly been reported (with a lower number of events in
summer than in autumn and winter) (5), we believe the analysis of
the variation of events across several years would also be mandatory
to conclude that the WTC tragedy was associated with an
increased risk of life-threatening ventricular arrhythmias in the
general population.
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REPLY
We appreciate the comments of Dr. Fauchier and colleagues
regarding our recent reports describing an increase in the incidence
of life-threatening ventricular arrhythmias in both New York City
(1) and Florida (2) in the aftermath of the World Trade Center
(WTC) attack.
A concern was raised that we did not compare the event rate of
2001 with a control period. In fact, we did compare the 30-day
period following September 2001 with 13 monthly periods after-
ward (including September 2002) and found the index month to
have a statistically higher arrhythmia event rate, with an odds ratio
of 2.5 (p 0.004) than all other monthly intervals (1). Thus, there
appeared to be a specific aberration temporally linked to the period
following the WTC attack, which was not attributable to seasonal
or monthly variation. We also noted that the study of cardiovas-
cular mortality in New York City (3) did not confirm a higher
death rate, but this form of analysis, using death certificates, is
fraught with inaccuracies in assessment of cause of death that may
make it insensitive for evaluating specific arrhythmic events.
Fauchier et al. state that if the events had concentrated in the
morning hours after the attack on September 11, this would lend
credence to our conclusions. However, as described (1), the event
rate did not increase on September 11, but did increase three days
later, and remained elevated for one month. In respect to the
diurnal variation of events, we surprisingly found a shift in the
preponderance of events to the evening instead of the morning
(J.S. Steinberg, unpublished observations, 2001), supporting spec-
ulation that stress was heightened by exposure to the graphic
scenes replayed by the media (1).
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Improved Outcomes of Pediatric Dilated
Cardiomyopathy and Heart Transplantation
The report by Tsirka et al. (1) provided a very useful update of the
outcomes for infants and children who develop dilated cardiomy-
opathy (DCM). Their use of a category combining death and
cardiac transplant (“heart death”) as end points was sensible and
helpful. However, some of the diagnostic categories were less than
fully explained and somewhat arbitrary. If patients with muscular
dystrophy (n  4) and inherited metabolic disorders (n  5), both
uniformly fatal diseases, were not included, their total population
of DCM would be only 82 instead of 91, and the population of
survivors with recovery of normal contractility would amount to
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40% of that population. This raises a serious question about
proceeding to transplantation in the first year of the disease, as four
centers have advised on the basis of their perception that DCM
had such a poor prognosis. In this published cohort, some
recovered as late as six years after onset; would 40% of the
transplanted children have recovered with normal contractility had
they not been transplanted?
Although the title of their study asserts that transplantation for
DCM will provide “improved outcomes,” that can only apply to
the first few years after cardiac transplantation, which lasts on
average 10 to 13 years. In contrast, 40% of all patients with DCM
recovered systolic function without transplantation and were still
normal eight years later. The difference between transplants and
complete recovery does not take into account the morbidity of
rejections and anti-immune treatments for the transplanted pa-
tients. If 40% of the transplanted children would have recovered,
the overall outcome would certainly not be improved.
Finally, the reliability of separating myocarditis from idiopathic
DCM is raised by their finding of no differences between the two
groups for either “heart death” or for recovery of function. This
important finding throws doubt on the criteria used to diagnose
myocarditis.
In sum, this important study by Tsirka et al. (1) provided several
important advances in our knowledge, even though the title made
promises that were unwarranted.
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REPLY
We appreciate Dr. Guntheroth’s remarks regarding our retrospec-
tive observational study (1) on pediatric dilated cardiomyopathy
(DCM). His concerns appropriately point out the limitation of all
observational studies—that one can never tell what would have
happened to the treated group (in this case those who were
transplanted) had they not undergone treatment because there is
no valid comparison group. However, 75% of the patients trans-
planted in our study were on persistent inotropic support (UNOS
status 1) at the time of transplant and had failed attempts to
remove inotropic support. Data from the Pediatric Heart Trans-
plant Study (PHTS) (2) suggest that inotropic support is a risk
factor for death before transplant. Thus, we believe our patients
who underwent transplantation represented a substantially sicker
subgroup of patients within the patient population studied. How-
ever, newer heart failure therapies such as beta-blockade have been
reported to remove the survival advantage from heart transplanta-
tion in adults (3) and to decrease utilization of heart transplanta-
tion in infants and children (4). The role of heart transplantation
as therapy for pediatric DCM needs to be continually redefined as
newer heart failure therapies are applied to pediatric heart disease.
Dr. Guntheroth suggests that inclusion of patients with DCM
from metabolic disease or muscular dystrophy may be misleading
because of the uniformly fatal nature of those diseases. The
differing natural history of the Becker and Duchenne variants of
dystrophin muscular dystrophy underscores the difficulties of
lumping all metabolic cardiomyopathies and muscular dystrophies
in one common prognostic group.
We would agree with Dr. Guntheroth that the criteria used in
our study to diagnose myocarditis are not clear cut. The frequency
of viral infection in children can make it likely that any diagnosis
of a DCM can generally correlate with a “recent” viral infection.
Pathologic criteria can also be confusing given the patchy nature of
myocardial inflammation leading to false negative endomyocardial
biopsies and the presence of viral genome in myocardial samples
without evidence of inflammation (5). Thus, any clear-cut defini-
tion of myocarditis in children remains difficult.
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Cell Transplantation and Fibrin Matrix
The recent study by Christman et al. (1) reports the results of an
experimental study that evaluated a “novel approach to heart repair
that uses an injectable biopolymer scaffold to deliver cells directly
into the infarct wall.” The researchers “hypothesized that the
injection of cells in a solution that becomes a semi-rigid scaffold
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